IMNR isn't much of an institutional stock. It isn't on the officially designated ok to buy list. In 1993 it was more so, but the hard times of failed efforts soured many to IMNR and to other biotechs. In most cases that attitude is justified because biotechnology is impossibly difficult, so it will be rare for any of them to create something more than poison.
IMNR's approach doesn't attempt to assume too much about human knowledge. It tries to work with the body, a homeopathic biotechnology. That doesn't mean they can necessarily be more successful. They may be the first to be significantly successful. I don't consider Amgen, Biogen, IMNX, etc., to be successful. They sold a lot of drugs and made a lot of money. So did the Colombians.
The biotech elite consider IMNR's approach half-baked and their personnel hacks. That may be true, but they are hard-working and thorough as scientists and non-pretentious as people. That company has suffered like I can't tell you. As you know they had to go to the well so many times that their knees wore out. Years of incredible pressure and failure. At one point several years ago I thought I would be receiving quarterlies on toilet paper. The staff worked six days a week unlimited hours for grammar school teacher's salaries. They aren't the big brain types, they just keep hammering away.
Remune and the RA drug regimen are only the beginning. Remune's value in terms of bottom line will come from the plethora of diseases that approach will be successful to address. Other diseases are far more amenable to treatment under the Remune style bio-engineering supplemented with other kinds of function specific drugs. Remune is an individual immune system specific mediator which emulates a disease impregnable genetic system response. It enables the body to act as though the body had a disease specific resistant genetic structure. This technique can be reproduced with different twists for different diseases. Thus, HIV help is only the beginning.
The stock is acting the way it should. When run up, it falls right back down to where it started plus an increment. It has a very flat uptrend. I can't tell you how bullish that is and though I've tried to tell unbelieving others, how unmanipulated and fair that is. There is no excesses in this stock. Like I've told you before, you can't operate with options here. You can't buy and hold. You can't write because of the kinds of jumps recently seen. The only way to be successful is to buy stock and ignore everything. That's why you see me here only rarely |
